Hematology

Latest News

FDA ODAC Committee’s 12-2 Vote Favors Benefit-Risk Profile of Imetelstat in Lower-Risk MDS
FDA ODAC Committee’s 12-2 Vote Favors Benefit-Risk Profile of Imetelstat in Lower-Risk MDS

March 15th 2024

The benefits of imetelstat outweigh the risks for anemia treatment in lower-risk myelodysplastic syndrome, according to a vote by the FDA’s Oncologic Drugs Advisory Committee.

Liso-Cel Receives FDA Approval for Relapsed or Refractory CLL/SLL
Liso-Cel Receives FDA Approval for Relapsed or Refractory CLL/SLL

March 15th 2024

Orca-T Provides Post-HCT Survival Benefits vs PTCy in Blood Cancers
Orca-T Provides Post-HCT Survival Benefits vs PTCy in Blood Cancers

March 4th 2024

Ocifisertib Receives Orphan Drug Designation From FDA for AML
Ocifisertib Receives Orphan Drug Designation From FDA for AML

March 3rd 2024

NCCN Recommends Ropeginterferon Alfa-2B as First-Line Cytoreductive Therapy for PV
NCCN Recommends Ropeginterferon Alfa-2B as First-Line Cytoreductive Therapy for PV

March 1st 2024

Video Interviews
Podcasts
The Vitals
The Vitals
Oncology Nursing News
Oncology Nursing Stories: Pregnancy After Lymphoma Chemoradiation
Stephanie Jackson Unpacks Recent Advances in Leukemia Treatments
When an Oncology Nurse Becomes a Cancer Mom: How One Nurse Navigated Her Child’s Leukemia Diagnosis
Latest CME Events & Activities

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

View More

From Trials to the Real World: Assessing the Role of Allogeneic Transplant and JAK Inhibitors as Treatment Paradigms Evolve in Myelofibrosis

View More

Expert Illustrations and Commentaries™: Evaluating the Potential for Novel Mechanistic Approaches to Overcome Clinical Gaps in the Care of Patients with LR-MDS

View More

Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?

View More

Clinical Vignettes™: Integrating Novel CAR T-Cell Therapies Across Lymphoid Malignancies with an Eye Toward the Future of Care

View More

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

View More

The Latest on Acute Lymphocytic Leukemia

View More

A Focus on Acute Myeloid Leukemia

View More

Updates in Myelodysplastic Syndromes

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Go To PER in Chicago

May 31, 2024 - June 2, 2024

Register Now!

Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

7th Annual Live Medical Crossfire®: Hematologic Malignancies

View More

Community Practice Connections™: Integrating BTK Inhibitors Into the CLL/SLL and MCL Treatment Paradigm

View More

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

View More

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?

View More

Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News

© 2024 MJH Life Sciences

All rights reserved.